High Blood Cholesterol - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

High Blood Cholesterol > What Your Doctor is Reading About High Blood Cholesterol > Review Articles

Review Articles

1. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.

Author: Knopp RH; Paramsothy P; Atkinson B; Dowdy A;
Institution: Division of Metabolism, Endocrinology and Nutrition, Northwest Lipid Research Clinic, Seattle, Washington, USA. rhknopp@u.washington.edu
Journal: Am J Cardiol. 2008 Apr 17;101(8A):48B-57B.
Abstract URL: Click here to view abstract

2. The role of soluble fiber in the management of patients with hypercholesterolemia: a review of the literature.

Author: Baker WL; White CM; Coleman CI;
Institution: Evidence-Based Practice Center, Hartford Hospital, USA. wbaker01@harthosp.org
Journal: Conn Med. 2008 Sep;72(8):465-8.

3. Comparison of different LDL apheresis methods.

Author: Julius U; Frind A; Tselmin S; Kopprasch S; Poberschin I; Siegert G;
Institution: University Hospital Dresden, Medical Clinic III, Fetscherstr. 74, 01307 Dresden, Germany. ulrich.julius@uniklinikum-dresden.de
Journal: Expert Rev Cardiovasc Ther. 2008 Jun;6(5):629-39.
Abstract URL: Click here to view abstract

4. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment.

Author: Majeed F; Miller M;
Institution: Department of Medicine, University of Maryland Medical Center, Baltimore, Maryland 21201, USA.
Journal: Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):175-81.
Abstract URL: Click here to view abstract

5. Dietary plant sterols and cholesterol metabolism.

Author: Ellegard LH; Andersson SW; Normen AL; Andersson HA;
Institution: Department of Clinical Nutrition, Sahlgrenska Academy at Goteborg University, Box 459, SE-413 90 Goteborg, Sweden Lasse.Ellegard@nutrition.gu.se
Journal: Nutr Rev. 2007 Jan;65(1):39-45.
Abstract URL: Click here to view abstract

6. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Author: deGoma EM; deGoma RL; Rader DJ;
Institution: Department of Cardiology, Stanford University Hospital, Stanford, California 94305, USA. edegoma@stanford.edu
Journal: J Am Coll Cardiol. 2008 Jun 10;51(23):2199-211.
Abstract URL: Click here to view abstract

7. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Author: Hausenloy DJ; Yellon DM;
Institution: The Hatter Cardiovascular Institute, University College London Hospital and Medical School, 67 Chenies Mews, London WC1E 6HX, UK.
Journal: Heart. 2008 Jun;94(6):706-14.
Abstract URL: Click here to view abstract

8. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.

Author: Miller M; Ginsberg HN; Schaefer EJ;
Institution: Division of Cardiology, University of Maryland Medical Center, Baltimore, MD, USA. mmiller@medicine.umaryland.edu <mmiller@medicine.umaryland.edu>
Journal: Am J Cardiol. 2008 Apr 1;101(7):1003-8.
Abstract URL: Click here to view abstract

9. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.

Author: Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM;
Institution: Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
Journal: Am J Cardiol. 2008 Jun 1;101(11):1606-13. Epub 2008 Apr 9.
Abstract URL: Click here to view abstract

10. Recommendations for the use of LDL apheresis.

Author: Thompson GR;
Institution: Imperial College, Hammersmith Hospital, London. g.thompson@imperial.ac.uk
Journal: Atherosclerosis. 2008 Jun;198(2):247-55. Epub 2008 Feb 19.
Abstract URL: Click here to view abstract

11. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials.

Author: Coleman CI; Reinhart K; Kluger J; White CM;
Institution
Journal: Curr Med Res Opin. 2008 May;24(5):1359-62. Epub 2008 Apr 1.
Abstract URL: Click here to view abstract

12. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia.

Author: Steinberg D; Glass CK; Witztum JL;
Institution: Department of Medicine, BSB 1080, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0682, USA. dsteinberg@ucsd.edu
Journal: Circulation. 2008 Aug 5;118(6):672-7.

13. Familial hypercholesterolemia: current treatment and advances in management.

Author: Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA;
Institution: Academic Medical Center, Department of Vascular Medicine, Meibergreef 9 (Room F4-146), 1105 AZ, Amsterdam, The Netherlands. r.huijgen@amc.uva.nl
Journal: Expert Rev Cardiovasc Ther. 2008 Apr;6(4):567-81.
Abstract URL: Click here to view abstract

14. Ezetimibe: cholesterol lowering and beyond.

Author: Bays HE; Neff D; Tomassini JE; Tershakovec AM;
Institution: Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. hbaysmd@aol.com
Journal: Expert Rev Cardiovasc Ther. 2008 Apr;6(4):447-70.
Abstract URL: Click here to view abstract

15. HDL: still a target for new therapies?

Author: Nicholls SJ;
Institution: Cleveland Clinic, Department of Cardiovascular Medicine, Heart & Vascular Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA. nichols1@ccf.org
Journal: Curr Opin Investig Drugs. 2008 Sep;9(9):950-6.
Abstract URL: Click here to view abstract

16. Hypercholesterolaemia and its management.

Author: Bhatnagar D; Soran H; Durrington PN;
Institution: University of Manchester Cardiovascular Research Group, Core Technology Facility, Manchester M13 9NT. d.bhatnagar@man.ac.uk
Journal: BMJ. 2008 Aug 21;337:a993. doi: 10.1136/bmj.a993.

17. Aortic sclerosis, aortic stenosis and lipid-lowering therapy.

Author: Rosenhek R; Baumgartner H;
Institution: Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Wien, Austria. raphael.rosenhek@meduniwien.ac.at
Journal: Expert Rev Cardiovasc Ther. 2008 Mar;6(3):385-90.
Abstract URL: Click here to view abstract

18. Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials.

Author: Kesaniemi A;
Institution: Department of Internal Medicine, Oulu University Hospital, Oulu, Finland. ayk@sun3.oulu.fi
Journal: Fundam Clin Pharmacol. 2007 Nov;21 Suppl 2:29-30.
Abstract URL: Click here to view abstract

19. New targets and emerging therapies for reducing LDL cholesterol.

Author: Lilly SM; Rader DJ;
Institution: Department of Medicine and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Journal: Curr Opin Lipidol. 2007 Dec;18(6):650-5.
Abstract URL: Click here to view abstract

20. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.

Author: Sweeney ME; Johnson RR;
Institution: Emory University School of Medicine, Division of Endocrinology, Metabolism and Lipids, Atlanta VA Medical Center-111, 1670 Clairmont Rd, Atlanta, GA 30033, USA. msweene@emory.edu
Journal: Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):441-50.
Abstract URL: Click here to view abstract

21. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.

Author: Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH;
Institution: kathyfox@comcast.net
Journal: Am J Manag Care. 2007 Dec;13 Suppl 10:S270-5.
Abstract URL: Click here to view abstract

22. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Author: Lewington S; Whitlock G; Clarke R; Sherliker P; Emberson J; Halsey J; Qizilbash N; Peto R; Collins R;
Institution: CTSU, University of Oxford, Oxford OX3 7LF, UK.
Journal: Lancet. 2007 Dec 1;370(9602):1829-39.
Abstract URL: Click here to view abstract

23. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.

Author: Schaefer EJ; Asztalos BF;
Institution: Cardiovascular Research and Lipid Metabolism Laboratories, Tufts University, Boston, Massachusetts 02111, USA. ernst.schaefer@tufts.edu
Journal: Am J Cardiol. 2007 Dec 3;100(11 A):n25-31.
Abstract URL: Click here to view abstract

24. Measuring cholesterol levels.

Author: Pottle A;
Institution: Harefield Hospital, Harefield, Middlesex. a.pottle@rbht.nhs.uk
Journal: Nurs Stand. 2007 Jul 25-31;21(46):42-7.
Abstract URL: Click here to view abstract

25. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?

Author: Ito MK;
Institution: College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland Campus at OHSU, 3303 SW Bond Ave., Portland, OR 97239, USA. itom@ohsu.edu
Journal: Ann Pharmacother. 2007 Oct;41(10):1669-78. Epub 2007 Sep 11.
Abstract URL: Click here to view abstract

26. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.

Author: Plakogiannis R; Cohen H;
Institution: Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA. roda.plakogiannis@liu.edu
Journal: Ann Pharmacother. 2007 Jan;41(1):106-10. Epub 2007 Jan 2.
Abstract URL: Click here to view abstract

27. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

Author: Rizzo M; Rini GB; Berneis K;
Institution: Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy. mrizzo@unipa.it
Journal: Adv Ther. 2007 May-Jun;24(3):575-82.
Abstract URL: Click here to view abstract

28. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.

Author: Alsheikh-Ali AA; Maddukuri PV; Han H; Karas RH;
Institution: Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Journal: J Am Coll Cardiol. 2007 Jul 31;50(5):409-18. Epub 2007 Jul 16.
Abstract URL: Click here to view abstract

29. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.

Author: Burnett JR;
Institution: Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
Journal: Curr Opin Mol Ther. 2006 Oct;8(5):461-7.
Abstract URL: Click here to view abstract

30. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.

Author: Thavendiranathan P; Bagai A; Brookhart MA; Choudhry NK;
Institution: Department of Medicine, University of Toronto, Toronto, Ontario.
Journal: Arch Intern Med. 2006 Nov 27;166(21):2307-13.
Abstract URL: Click here to view abstract

31. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.

Author: Burnett JR; Huff MW;
Institution: Royal Perth Hospital, Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Wellington Street Campus, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
Journal: Expert Opin Investig Drugs. 2006 Nov;15(11):1337-51.
Abstract URL: Click here to view abstract

32. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?

Author: Jacobson TA;
Institution: Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA. tjaco02@emory.edu
Journal: Mayo Clin Proc. 2006 Sep;81(9):1225-31.
Abstract URL: Click here to view abstract

33. Cholesterol management.

Author: Griffith K;
Institution: Primary Care Cardiovascular Society, USA.
Journal: Practitioner. 2006 Sep;250(1686):23-4, 26, 29.

34. Nutriceuticals in cardiovascular disease: psyllium.

Author: Petchetti L; Frishman WH; Petrillo R; Raju K;
Institution: Department of Medicine, Mt. Vernon Hospital, Mt. Vernon, New York, USA.
Journal: Cardiol Rev. 2007 May-Jun;15(3):116-22.
Abstract URL: Click here to view abstract

35. Mechanisms of disease: HDL metabolism as a target for novel therapies.

Author: Rader DJ;
Institution: Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104, USA. rader@mail.med.upenn.edu
Journal: Nat Clin Pract Cardiovasc Med. 2007 Feb;4(2):102-9.
Abstract URL: Click here to view abstract

36. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence.

Author: Patch CS; Tapsell LC; Williams PG; Gordon M;
Institution: National Centre of Excellence in Functional Foods, Northfields Avenue, University of Wollongong, New South Wales, Australia. cpatch@nceff.com.au
Journal: Vasc Health Risk Manag. 2006;2(2):157-62.
Abstract URL: Click here to view abstract

37. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination.

Author: Neal RC; Jones PH;
Institution: Baylor College of Medicine, Section of Lipid and Atherosclerosis, Houston, TX 77030, USA. rneal@bcm.tmc.edu
Journal: Vasc Health Risk Manag. 2006;2(1):31-8.
Abstract URL: Click here to view abstract

38. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.

Author: Hayward RA; Hofer TP; Vijan S;
Institution: Department of Veterans Affairs, VA Center for Practice Management and Outcomes Research, VA Ann Arbor Healthcare System, and University of Michigan Schools of Medicine and Public Health, Ann Arbor, Michigan 48113-0170, USA. rhayward@umich.edu
Journal: Ann Intern Med. 2006 Oct 3;145(7):520-30.
Abstract URL: Click here to view abstract

39. The evolution of European guidelines: changing the management of cholesterol levels.

Author: Erhardt LR; Gotto A Jr;
Institution: Department of Cardiology, Cardiology Research Unit, University of Lund, Malmo University Hospital, SE-205 02 Malmo, Sweden. leif.erhardt@med.lu.se
Journal: Atherosclerosis. 2006 Mar;185(1):12-20. Epub 2005 Nov 23.
Abstract URL: Click here to view abstract

40. Plant sterols combined with exercise for the treatment of hypercholesterolemia: overview of independent and synergistic mechanisms of action.

Author: Marinangeli CP; Varady KA; Jones PJ;
Institution: School of Dietetics and Human Nutrition, McGill University, Quebec, Canada.
Journal: J Nutr Biochem. 2006 Apr;17(4):217-24. Epub 2005 Oct 10.
Abstract URL: Click here to view abstract

41. Low-density lipoprotein reduction: is the risk worth the benefit?

Author: Sabharwal AK; Boord JB;
Institution: VA Tennessee Valley Geriatrics Research, Education, and Clinical Center, 1310 24th Avenue South, Nashville, TN 37212, USA.
Journal: Curr Atheroscler Rep. 2006 Jan;8(1):19-25.
Abstract URL: Click here to view abstract

42. Systematic review, meta-analysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol.

Author: Harland JI; Haffner TA;
Institution: HarlandHall Associates, The Stables, Ranbury Ring, London Road, Poulton, Cirencester, Glos GL7 5HN, UK. jan.harland@harlandhall.co.uk
Journal: Atherosclerosis. 2008 Sep;200(1):13-27. Epub 2008 Apr 15.
Abstract URL: Click here to view abstract

43. Combination therapy in the management of mixed dyslipidaemia.

Author: Cannon CP;
Institution: Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. cpcannon@partners.org
Journal: J Intern Med. 2008 Apr;263(4):353-65.
Abstract URL: Click here to view abstract

44. Pharmacological therapies for raising HDL cholesterol beyond synthetic small molecules.

Author: Garcia RA;
Institution: University of California, San Diego, Department of Medicine, 9500 Gilman Dr, 0613J, BSB 2004, La Jolla, CA 92093, USA. r5garcia@ucsd.edu
Journal: Curr Opin Investig Drugs. 2008 Mar;9(3):274-80.
Abstract URL: Click here to view abstract

45. Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy.

Author: Hoenig MR; Rolfe BE; Campbell JH;
Institution: Royal Brisbane and Women's Hospital, Level 5 Pigeon Holes, Herton Road, Herston, Brisbane, Qld 4029, Australia. ebalk@tufts-nemc.org
Journal: Atherosclerosis. 2006 Feb;184(2):247-54. Epub 2005 Oct 7.
Abstract URL: Click here to view abstract

46. High-density lipoprotein cholesterol-raising strategies.

Author: Kuvin JT; Alsheikh-Ali AA; Karas RH;
Institution: Division of Cardiology, Department of Medicine, Tufts-New England Medical Center, Tufts University School of Medicine Boston, Massachusettes 0211, USA. jkuvin@tufts-nemc.org
Journal: J Cardiovasc Pharmacol. 2006 Feb;47(2):196-204.
Abstract URL: Click here to view abstract

47. Update on lipid-lowering therapy and LDL-cholesterol targets.

Author: Wiviott SD; Cannon CP;
Institution: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. swiviott@partners.org
Journal: Nat Clin Pract Cardiovasc Med. 2006 Aug;3(8):424-36.
Abstract URL: Click here to view abstract

48. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines.

Author: Hennekens CH; Hollar D; Eidelman RS; Agatston AS;
Institution: Miller School of Medicine, University of Miami, Miami, Florida, USA. profchhmd@prodigy.net
Journal: MedGenMed. 2006 Feb 23;8(1):54.
Abstract URL: Click here to view abstract

49. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases.

Author: Choi BG; Vilahur G; Yadegar D; Viles-Gonzalez JF; Badimon JJ;
Institution: Cardiovascular Biology Research Laboratory, Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Journal: Curr Mol Med. 2006 Aug;6(5):571-87.
Abstract URL: Click here to view abstract

50. How safe is aggressive statin therapy?

Author: Guthrie RM;
Institution: The Ohio State University College of Medicine, Columbus, OH 43212, USA. guthrie.1@osu.edu
Journal: Prog Cardiovasc Nurs. 2006 Summer;21(3):140-5.
Abstract URL: Click here to view abstract

51. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Author: Chrysant SG; Ibrahim M;
Institution: Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, 73132-4904, USA. schrysant@yahoo.com
Journal: J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1.
Abstract URL: Click here to view abstract

52. Lipid-lowering therapy in high-risk persons.

Author: Aronow WS;
Institution: Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA. WSAronow@aol.com
Journal: Compr Ther. 2006 Summer;32(2):68-73.
Abstract URL: Click here to view abstract

53. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.

Author: Duffy D; Rader DJ;
Institution: Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Journal: Circulation. 2006 Feb 28;113(8):1140-50.

54. Statin therapy for coronary heart disease and its effect on stroke.

Author: Switzer JA; Hess DC;
Institution
Journal: Curr Atheroscler Rep. 2006 Jul;8(4):337-42.
Abstract URL: Click here to view abstract